Technopark TBI Virtual Incubatee Catalyz Scientific Technologies bags ISBA Award for the Best Start

February 7th, 2010|

Catalyz is developing affordable diagnostic and care systems for infectious and chronic diseases. The tests need no technical knowledge or any device to interpret the result, hence making it easy for a lame man in confirming or ruling out certain diseases.

Indoco, Watson Pharma in generics deal

February 3rd, 2010|

Under this deal, Indoco will develop, manufacture and supply a number of products that have total yearly sales of $679 million at present.

Indias First Healthcare, Beauty & Wellness Franchising Report launched by Franchise India at the Kno

January 28th, 2010|

Franchise India Holdings limited in association with Francorp and Medium Healthcare Consulting Pvt Ltd has organized a two day workshop on Business of Healthcare, Wellness and Beauty at Taj Lands End, Mumbai. On the occasion India’s First Healthcare, Wellness and Beauty Franchising Report was launched by Mr. Ratan Jalaan, Founder, Medium Healthcare Marketing and Mr. Sachin Marya, CEO & Publisher, Franchise India Holdings Limited.

Opportunities for NRIs to invest in pharma sector in India

January 9th, 2010|

Union Health and Family Welfare Minister Ghulam Nabi Azad and Gujarat Chief Minister Narendra Modi, on Saturday invited expatriates to invest in the country.

GSK inching closer to deal with Dr Reddys?

January 8th, 2010|

Citing people familiar with the matter, reported that Glaxo will take a 20-per cent stake in Dr. Reddy's Holdings Ltd., a family vehicle that owns 23.2 per cent of the Hyderabad-based Dr Reddy's Laboratories.

Life science firms up hirings

January 8th, 2010|

As domestic pharma and life science companies aggressively scale up their R&D capabilities to meet the rising demand for clinical research from global majors, they are back in the job market to scout and woo talent with attractive salary packages.

Bafna Pharma to focus mainly on life-style products

January 8th, 2010|

Bafna Pharmaceuticals,shall be focussing mainly on life-style products, the company chariman and managing director, Mahaveer Chand, disclosed, in an exclusive interview with

Challenges to domestic drug patents grow

January 8th, 2010|

Domestic drug companies, who have been challenging drug patents in the US and Europe, are now taking the first steps to challenge patents granted in India to companies based there.

Strides Arcolabs looks to seal more drug supply deals with global pharma cos

January 8th, 2010|

Strides Acrolabs, which struck a drug supply deal with Pfizer on Wednesday, said it is discussing similar drug supply deal for niche therapeutics areas with global drug pharma companies. The Bangalore-based company will start getting part of the money from its deal with Pfizer this quarter onwards and that such deals would drive its future growth, a senior company executive said.

Novartis to leapfrog Alcon deal

January 8th, 2010|

In one stroke, Swiss pharma giant Novartis AG could break into the league of top five players in the Rs 600-crore plus Indian eyecare market from its current position at 13, if its takeover of Alcon goes through seamlessly and eventually results in integration of Alcon India into the Indian arm of Novartis. Such a combined entity of Novartis and Alcon would then command a marketshare of 7.5% in the domestic eyecare market, just 1.4% less compared with the third and fourth ranked companies, FDC and Sun Pharma, which command 8.9% marketshare each.

Domestic producers look for more of pharmaceutical rebound

January 8th, 2010|

The pharmaceutical market in Russia managed to grow by more than 25% in 2009 despite the economic downturn. But domestic producers are still losing out to their foreign rivals.

Pfizer, Like Much of Big Pharma, Pushes Further Into Generics

January 7th, 2010|

The distance between Big Pharma and the generic drugs business keeps getting narrower. Under a deal with an Indian drugs shop Strides Arcolab, Pfizer will add some 40 off-patent drugs, including many cancer medicines, to the list of products it sells in the U.S. Here’s a statement Pfizer put out describing the deal.

Pharmaceutical sector has capacity to double exports in five years

January 7th, 2010|

* At least $1 billion incremental gains in export expected by 2014 Pakistan’s pharmaceutical sector has the potential to double its export in next five years provided pricing and contracting challenges are addressed in an efficient way, according to a draft of an official study.

Piramal Healthcare to raise Rs 10 bn in 6-8 months

January 7th, 2010|

Pharmaceutical major Piramal Healthcare is planning to raise Rs 1,000 crore (Rs 10 billion) in the next 6-8 months, a senior company official said here on Thursday.

Cadila Healthcare sets April date for the launch of H1N1 vaccine

January 7th, 2010|

Ahmedabad-based Cadila Healthcare Ltd could well be the first Indian company to launch the H1N1 vaccine in India. It expects to bring its vaccine in the market by April 2010.  

Pharma industry urges govt to withdraw WHO study on ‘data exclusivity

January 7th, 2010|

The domestic pharmaceutical industry has urged the government to withdraw a study launched by the World Health Organization (WHO) in consultation with the Union ministry of health on implementing 'Data Exclusivity' in India.

Govt to examine Suns breast cancer drug

January 5th, 2010|

The government will examine Sun Pharma’s post marketing surveillance studies (PMS) and clinical trials report of breast cancer medicine Letrox (chemical name letrozole) to decide whether the drug should be banned from being marketed, as an anti-infertility drug among young women.

Dishman sees Crams biz growing 20 percent

January 5th, 2010|

Dishman Chemicals and Pharmaceuticals, the Ahmedabad-based leading player in the contract research and manufacturing services (Crams) space, is expecting growth of about 20% in the segment starting next fiscal.

Pharma cos see opportunity in India

January 5th, 2010|

The year had just begun, when Pfizer announced its $68-billion deal to acquire Wyeth, in January. On its heels came Merck & Co's $ 41-billion deal to acquire Schering-Plough Corporation, in March.

TCG Lifesciences, Pfizer ink drug research pact

January 5th, 2010|

TCG Lifesciences, the Rs 400-crore clinical research organisation (CRO) venture of the Chatterjee Group, has entered into an exclusive collaboration with the US-based pharma giant, Pfizer, to develop a portfolio of pre-clinical molecules for discovery of new drugs.